Most New Drugs Never Make it to Market

The amazing speed with which the pharmaceutical industry developed, tested and won emergency approval for the COVID-19 vaccine was not just surprising, but in at least one way, misleading.

As the new report, Clinical Development Success Rates and Contributing Factors 2011 – 2020 from Bio.org makes clear, the COVID vaccines and therapeutics that became available mere months into the pandemic were a dramatic and rare exception.

On average, the report tells us it takes almost 11 years to go from a Phase I program to regulatory approval. And that’s only for those drugs and therapies that make it through. Over the 10 years from 2011, the likelihood that a drug in a Phase I trial would ultimately win approval was 7.9%.

That may be better odds than winning the Powerball lottery, however, the investment in a drug’s development can dwarf all but the largest jackpots. Making it even more of a gamble for a pharmaceutical firm is that the average success rate has declined since Bio’s 2016 report. Then the average for the previous 10 years was 9.6%.

Heavy with tables, charts and graphs, the Bio.org report (in conjunction with Informa Pharma Intelligence and QLS Advisors) reviews success rates across 21 major diseases. It reports specifics on 14 of them, combining the balance into an “Other” category. The detailed diseases are: Allergy, Autoimmune, Cardiovascular, Endocrine, Gastroenterology (non-IBD), Hematology, Infectious disease, Metabolic, Neurology, Oncology, Ophthalmology, Psychiatry, Respiratory, and Urology.

Comparing the success rates in the current report to the previous one, Bio found 12 categories had a lower likelihood of progressing from Phase 1 to approval. The largest decline was in urology. In the 2016 report, therapeutics in this category averaged 11.4% success. In the recent report, the average fell to 3.6%.

Hematology has the highest likelihood of approval at 23.9%, though it too saw a decline from 26.1%.

Drugs to treat rare diseases fared better than other therapies. The report said these drugs had a 17% likelihood of success.

The decrease, explains a Bio.org discussion of the report, “Can be attributed to two main factors: A greater participation from smaller firms participating in drug candidate development and their willingness to disclose early failures.”

Said David Thomas, BIO VP, industry research, “That all ties into what we see, which is a lower success rate overall from our last paper in 2016.”

Drug development remains difficult with far less than 1 in 10 clinical drug programs ever reaching patients,” says the Bio.org account. “It usually takes 10 to 10.5 years to develop a vaccine, which makes the existing COVID-19 vaccines on the market all the more incredible.”

Success, adds Thomas, takes “many shots on goal.”

Photo by ThisisEngineering RAEng on Unsplash

#WeAreGreenKey: Spotlight on Reilly Hickey
General Interest Green Key News Human Resources Professional Support Worklife

#WeAreGreenKey: Spotlight on Reilly Hickey

Green Key Unlocked: Keys to Success in Agency Recruiting
General Interest Green Key News Worklife

Green Key Unlocked: Keys to Success in Agency Recruiting

Resume Tricks for 2022
General Interest Green Key News Worklife

Resume Tricks for 2022

#WeAreGreenKey: Spotlight on Kornelia Klukowska
Accounting + Finance General Interest Green Key News Worklife

#WeAreGreenKey: Spotlight on Kornelia Klukowska

When to Say Goodbye to a Candidate
General Interest Green Key News Worklife

When to Say Goodbye to a Candidate

#WeAreGreenKey: Spotlight on Allison Vogt
General Interest Green Key News Worklife

#WeAreGreenKey: Spotlight on Allison Vogt

Green Key Unlocked: The Growth of Professional Support
General Interest Green Key News Professional Support Worklife

Green Key Unlocked: The Growth of Professional Support

#WeAreGreenKey: Spotlight on Brittany Leader
General Interest Green Key News Healthcare Worklife

#WeAreGreenKey: Spotlight on Brittany Leader

Green Key Unlocked: FAQs of Working with a Recruiter
General Interest Green Key News Pharma Worklife

Green Key Unlocked: FAQs of Working with a Recruiter

Green Key Announces New Senior Partners
General Interest Green Key News Worklife

Green Key Announces New Senior Partners

Green Key Against Gun Violence
General Interest Green Key News

Green Key Against Gun Violence

How to Support Mental Health in the Workplace
General Interest Green Key News Worklife

How to Support Mental Health in the Workplace

#WeAreGreenKey: Spotlight on Larry Goodman
General Interest Green Key News Pharma Worklife

#WeAreGreenKey: Spotlight on Larry Goodman

#WeAreGreenKey: Spotlight on Mike Glock
Accounting + Finance Financial Services General Interest Worklife

#WeAreGreenKey: Spotlight on Mike Glock

How to Make Your Candidate an Attractive Offer
General Interest Green Key News Worklife

How to Make Your Candidate an Attractive Offer

Tips for Recent Grads
General Interest Green Key News Worklife

Tips for Recent Grads

#WeAreGreenKey: Spotlight on Patrick Friel
Accounting + Finance General Interest Green Key News Worklife

#WeAreGreenKey: Spotlight on Patrick Friel

Working Moms at GKR
General Interest Green Key News Healthcare Human Resources Pharma Professional Support Worklife

Working Moms at GKR

Green Key Resources Opens New Jersey Office
General Interest Green Key News Worklife

Green Key Resources Opens New Jersey Office

#WeAreGreenKey: Spotlight on Tim Durkin
Accounting + Finance General Interest Green Key News Worklife

#WeAreGreenKey: Spotlight on Tim Durkin

Latest Blog Posts
View All Posts
#WeAreGreenKey: Spotlight on Reilly Hickey

#WeAreGreenKey: Spotlight on Reilly Hickey

Reilly graduated from Pace University in 2018 with a degree in Arts & Entertainment Management. She worked in casting for...
Read More
Green Key Unlocked: Keys to Success in Agency Recruiting

Green Key Unlocked: Keys to Success in Agency Recruiting

Becoming a successful recruiter is no easy feat. Staffing is an industry that requires specific skills and persistence in order...
Read More
Resume Tricks for 2022

Resume Tricks for 2022

To keep you on top of the resume trends, we've put together a comprehensive list of tricks and tips to...
Read More